Abstract | PURPOSE:
Pyrazoloacridine (PZA), a rationally synthesized deoxyribonucleic acid ( DNA) binding agent that preferentially inhibits ribonucleic acid rather than DNA synthesis, is active against hypoxic and noncycling tumor cells and has greater in vitro activity against a broad range of human solid tumor lines than against the L1210 murine leukemia line. The Pediatric Oncology Group conducted a phase II study to determine the activity of PZA administered as a 3-hour infusion. PATIENTS AND METHODS: RESULTS: A total of 47 patients were entered into the study. Myelosuppression was the primary toxicity. Severe nonhematologic toxicity was uncommon. Only one patient exhibited grade 3 neurologic toxicity (anxiety). No CRs or PRs were observed. CONCLUSION: Use of the global stopping criterion permitted early identification of lack of activity of PZA against childhood solid tumors.
|
Authors | S L Berg, S M Blaney, J Sullivan, M Bernstein, R Dubowy, M B Harris, Pediatric Oncology Group |
Journal | Journal of pediatric hematology/oncology
(J Pediatr Hematol Oncol)
2000 Nov-Dec
Vol. 22
Issue 6
Pg. 506-9
ISSN: 1077-4114 [Print] United States |
PMID | 11132217
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Acridines
- Antineoplastic Agents
- Pyrazoles
- NSC 366140
|
Topics |
- Acridines
(adverse effects, therapeutic use)
- Adolescent
- Adult
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Anxiety
- Child
- Child, Preschool
- Humans
- Infant
- Neoplasms
(drug therapy)
- Patient Selection
- Pyrazoles
(adverse effects, therapeutic use)
- Thrombocytopenia
(chemically induced)
|